Forte Biosciences Crescita futura
Future criteri di controllo 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Forte Biosciences.
Informazioni chiave
n/a
Tasso di crescita degli utili
n/a
Tasso di crescita dell'EPS
Biotechs crescita degli utili | 27.1% |
Tasso di crescita dei ricavi | n/a |
Rendimento futuro del capitale proprio | n/a |
Copertura analitica | Low |
Ultimo aggiornamento | 03 Sep 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Forte Biosciences files for $300M mixed shelf offering
May 28Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
Dec 18Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Forte Biosciences readies equity offering
Oct 28Previsioni di crescita degli utili e dei ricavi
Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
---|---|---|---|---|---|
12/31/2026 | N/A | N/A | N/A | N/A | 1 |
12/31/2025 | N/A | N/A | N/A | N/A | 2 |
12/31/2024 | N/A | N/A | N/A | N/A | 2 |
6/30/2024 | N/A | -36 | -31 | -31 | N/A |
3/31/2024 | N/A | -32 | -30 | -30 | N/A |
12/31/2023 | N/A | -31 | -29 | -29 | N/A |
9/30/2023 | N/A | -30 | -23 | -23 | N/A |
6/30/2023 | N/A | -24 | -16 | -16 | N/A |
3/31/2023 | N/A | -18 | -11 | -11 | N/A |
12/31/2022 | N/A | -14 | -8 | -8 | N/A |
9/30/2022 | N/A | -12 | -9 | -9 | N/A |
6/30/2022 | N/A | -17 | -12 | -12 | N/A |
3/31/2022 | N/A | -19 | -15 | -15 | N/A |
12/31/2021 | N/A | -22 | -17 | -17 | N/A |
9/30/2021 | N/A | -23 | -17 | -17 | N/A |
6/30/2021 | N/A | -20 | -20 | -20 | N/A |
3/31/2021 | N/A | -49 | -20 | -20 | N/A |
12/31/2020 | N/A | -46 | -18 | -18 | N/A |
9/30/2020 | N/A | -43 | -15 | -15 | N/A |
6/30/2020 | N/A | -39 | -8 | -8 | N/A |
3/31/2020 | N/A | -5 | -5 | -5 | N/A |
12/31/2019 | N/A | -4 | -3 | -3 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: Insufficient data to determine if FBRX's forecast earnings growth is above the savings rate (2.5%).
Guadagni vs Mercato: Insufficient data to determine if FBRX's earnings are forecast to grow faster than the US market
Guadagni ad alta crescita: Insufficient data to determine if FBRX's earnings are expected to grow significantly over the next 3 years.
Ricavi vs Mercato: Insufficient data to determine if FBRX's revenue is forecast to grow faster than the US market.
Ricavi ad alta crescita: FBRX is forecast to have no revenue next year.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Insufficient data to determine if FBRX's Return on Equity is forecast to be high in 3 years time